Study of Pelabresib and Ruxolitinib for Myelofibrosis
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a combination of two drugs (pelabresib and ruxolitinib) for people with myelofibrosis whose spleen is enlarged and who have bothersome symptoms. It aims to see if adding pelabresib to standard care helps control the disease better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of myelofibrosis (primary or linked to another blood condition).
- Your risk category must be at least intermediate-1 (medium risk) or higher on the DIPSS scale.
- Your spleen must be enlarged to at least 450 cubic centimeters on a scan.
- You should have significant symptoms (like fatigue, pain, or fever) that score 15 or more on a symptom checklist.
- Your platelet count must be at least 100,000 per microliter of blood, without needing blood transfusions or growth factors for the last month.
- You cannot have had prior treatment with JAK inhibitors (like ruxolitinib) or BET inhibitors.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
This trial tests whether adding abemaciclib to ongoing ruxolitinib can better control myelofibrosis in people who are not getting enough benefit from ruxolitinib alone. It is designed to see safety and response in a specific group with intermediate-2 or high-risk disease and ongoing symptoms or enlarged spleen.
This trial tests a new drug called revumenib, which is being studied for people with myelofibrosis. Revumenib may help slow the disease and improve symptoms. The study has two parts: one for people who have already tried a JAK inhibitor, and one for those currently on a JAK inhibitor but still have active disease.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Hear when a new Primary Myelofibrosis (PMF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.